|
 |
Trial Information
Summary: Phase III clinical trial to evaluate the use effectiveness of Bevicizumab in combination with Tarceva in the treatment of lung cancer.Condition = Advanced non-small cell lung cancer Phase = Phase III The study will evaluate if adding Bevicizumab to the current treatment of Tarceva will increase the effectiveness of the lung cancer treatment. Patient Inclusion Criteria = Stage IIIB or
stage IV non-small cell lung cancer Patient Exclusion Criteria = Untreated cancer that has spread to the brain Primary Outcomes = The effectiveness of the
study will be measured by the survival rates of the patients
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received. This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Trial listings updated: February 25, 2008 at 2:31:13 PM |
|
|
Patient Resources: [ Trial Listing
] [ Notification Services ] [ Drug
Directories ]
Copyright © 1995 - 2008, CenterWatch |
